Clinuvel Logo press release scenesse Total Orphan Drugs

In by CameronLeave a Comment

Clinuvel Pharmaceuticals Limited today announced that a physician-led Phase II study of SCENESSE (afamelanotide 16mg implant) in patients with the rare Hailey-Hailey Disease (HHD) has commenced in Italy. This study will enrol ten HHD patients to be treated with twelve doses of SCENESSE during one year, with a three month clinical follow up period. Recruitment of all patients is expected to complete by March 2014.

Leave a Comment